Cargando…

Familial Colorectal Cancer Type X

The genetic background is unknown for the 50-60% of the HNPCC families, who fulfill the Amsterdam criteria, but do not have a mutation in an MMR gene, and is referred to as FCCTX. This study reviews the clinical, morphological and molecular characteristics of FCCTX, and discusses the molecular genet...

Descripción completa

Detalles Bibliográficos
Autores principales: Zetner, Diana Bregner, Bisgaard, Marie Luise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635618/
https://www.ncbi.nlm.nih.gov/pubmed/29081690
http://dx.doi.org/10.2174/1389202918666170307161643
_version_ 1783270325186723840
author Zetner, Diana Bregner
Bisgaard, Marie Luise
author_facet Zetner, Diana Bregner
Bisgaard, Marie Luise
author_sort Zetner, Diana Bregner
collection PubMed
description The genetic background is unknown for the 50-60% of the HNPCC families, who fulfill the Amsterdam criteria, but do not have a mutation in an MMR gene, and is referred to as FCCTX. This study reviews the clinical, morphological and molecular characteristics of FCCTX, and discusses the molecular genetic methods used to localize new FCCTX genes, along with an overview of the genes and chromosomal areas that possibly relate to FCCTX. FCCTX is a heterogeneous group, mainly comprising cases caused by single high-penetrance genes, or by multiple low-penetrance genes acting together, and sporadic CRC cases. FCCTX differs in clinical, morphological and molecular genetic characteristics compared to LS, including a later age of onset, distal location of tumours in the colon, lower risk of developing extracolonic tumours and a higher adenoma/carcinoma ratio, which indicates a slower progression to CRC. Certain characteristics are shared with sporadic CRC, e.g. similarities in gene expression and a high degree of CIN+, with significanly increased 20q gain in FCCTX. Other molecular characteristics of FCCTX include longer telomere length and hypomethylation of LINE-1, both being a possible explanation for CIN+. Some genes in FCCTX families (RPS20, BMPR1A, SEMA4A) have been identified by using a combination of linkage analysis and sequencing. Sequencing strategies and subsequent bioinformatics are improving fast. Exome sequencing and whole genome sequencing are currently the most promising tools. Finally, the involvement of CNV’s and regulatory sequences are widely unexplored and would be interesting for further investigation in FCCTX.
format Online
Article
Text
id pubmed-5635618
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-56356182018-02-01 Familial Colorectal Cancer Type X Zetner, Diana Bregner Bisgaard, Marie Luise Curr Genomics Article The genetic background is unknown for the 50-60% of the HNPCC families, who fulfill the Amsterdam criteria, but do not have a mutation in an MMR gene, and is referred to as FCCTX. This study reviews the clinical, morphological and molecular characteristics of FCCTX, and discusses the molecular genetic methods used to localize new FCCTX genes, along with an overview of the genes and chromosomal areas that possibly relate to FCCTX. FCCTX is a heterogeneous group, mainly comprising cases caused by single high-penetrance genes, or by multiple low-penetrance genes acting together, and sporadic CRC cases. FCCTX differs in clinical, morphological and molecular genetic characteristics compared to LS, including a later age of onset, distal location of tumours in the colon, lower risk of developing extracolonic tumours and a higher adenoma/carcinoma ratio, which indicates a slower progression to CRC. Certain characteristics are shared with sporadic CRC, e.g. similarities in gene expression and a high degree of CIN+, with significanly increased 20q gain in FCCTX. Other molecular characteristics of FCCTX include longer telomere length and hypomethylation of LINE-1, both being a possible explanation for CIN+. Some genes in FCCTX families (RPS20, BMPR1A, SEMA4A) have been identified by using a combination of linkage analysis and sequencing. Sequencing strategies and subsequent bioinformatics are improving fast. Exome sequencing and whole genome sequencing are currently the most promising tools. Finally, the involvement of CNV’s and regulatory sequences are widely unexplored and would be interesting for further investigation in FCCTX. Bentham Science Publishers 2017 -08 2017 -08 /pmc/articles/PMC5635618/ /pubmed/29081690 http://dx.doi.org/10.2174/1389202918666170307161643 Text en © 2017 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Zetner, Diana Bregner
Bisgaard, Marie Luise
Familial Colorectal Cancer Type X
title Familial Colorectal Cancer Type X
title_full Familial Colorectal Cancer Type X
title_fullStr Familial Colorectal Cancer Type X
title_full_unstemmed Familial Colorectal Cancer Type X
title_short Familial Colorectal Cancer Type X
title_sort familial colorectal cancer type x
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635618/
https://www.ncbi.nlm.nih.gov/pubmed/29081690
http://dx.doi.org/10.2174/1389202918666170307161643
work_keys_str_mv AT zetnerdianabregner familialcolorectalcancertypex
AT bisgaardmarieluise familialcolorectalcancertypex